What Is Zegalogue Used For?
Zegalogue (dasiglucagon) is an injectable glucagon analog approved to treat severe hypoglycemia in people with diabetes aged 6 years and older. It raises blood glucose levels quickly during emergencies when oral carbs aren't possible, such as unconsciousness or seizures from low blood sugar.[1]
How Does Zegalogue Work?
It mimics natural glucagon, prompting the liver to release stored glucose into the bloodstream within 30 minutes. A single 0.6 mg prefilled syringe delivers the dose subcutaneously—no reconstitution needed, unlike older glucagon kits.[1]
Who Needs It and When?
Prescribed for diabetics on insulin at risk of severe lows, including type 1 and type 2 patients. Caregivers or patients self-administer during symptoms like confusion, sweating, or unresponsiveness. Not for mild hypoglycemia or chronic low blood sugar management.[1]
How Does It Compare to Other Glucagon Options?
| Treatment | Form | Prep Time | Shelf Life | Key Difference |
|-----------|------|-----------|------------|---------------|
| Zegalogue | Prefilled syringe | Ready-to-use | 12 months at room temp | Faster, needle-free alternative to kits |
| Glucagon Emergency Kit (Eli Lilly) | Powder + syringe | 2-minute mixing | Refrigerate | Cheaper generic versions available |
| Baqsimi (nasal) | Nasal spray | Ready-to-use | Room temp | No needle, but less reliable in some studies |
Zegalogue edges out on ease but costs more upfront.[1][2]
What Side Effects Do Users Report?
Common: nausea (25%), vomiting (10%), headache. Rare: high blood pressure, allergic reactions. Inject into thigh or abdomen; monitor glucose after 15 minutes. Overdose risks hypertension.[1]
Dosage and Storage Details
One 0.6 mg dose per event; repeat if needed after carbs. Store at up to 86°F (30°C) for 12 months unopened. Discard if discolored or past expiry.[1]
Who Makes Zegalogue and Availability?
Zealand Pharma developed it; Novo Nordisk markets in the US since 2021 FDA approval. Covered by many insurers for diabetics; list price around $300 per kit.[1]
Patent and Exclusivity Timeline
US patents cover dasiglucagon formulation through 2036, with pediatric exclusivity to 2039. No generics yet; challenges unlikely soon.3
[1]: https://www.zegalogue.com/
[2]: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/dasiglucagon-injection-zegalogue-information